Biomea Fusion reports early weight loss and tolerability data for BMF-650
+1 new source since this summary was written
On October 13, 2026, Biomea Fusion reported Phase 1 results for its oral GLP-1 receptor agonist BMF-650. In outpatient Cohorts 1-4, mean Day 29 weight reduction ranged from 1.5% to 3.2%, versus 0.1% for pooled placebo, while a confined fifth cohort recorded 6.1% weight reduction. Across 40 active-dose participants, all treatment-emergent adverse events were mild or moderate, with no severe or serious events, dose modifications, or discontinuations related to adverse events.
Why it matters
Biomea said further development will require longer-term toxicology studies and that it plans to position BMF-650 for a strategic partnership. The readout supplies an early efficacy and tolerability datapoint, while additional development and commercialization plans remain ahead.
Key facts
- 1Mean Day 29 weight reduction in outpatient Cohorts 1-4 ranged from 1.5% to 3.2%, compared with 0.1% for pooled placebo. investing.com
- 2The confined fifth cohort showed mean Day 29 weight reduction of 6.1%. investing.com
- 3The five active-dose cohorts included 40 participants, and no severe or serious treatment-emergent adverse events were reported. investing.com
Open questions
- The confined fifth-cohort result has a comparability caveat because the company said confinement appeared to affect eating behavior and two placebo participants showed similar weight reduction.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.